Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer

Clinical trial NCT06848439 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06848439
Sponsor: Jiangsu Cancer Institute & Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Mouth Neoplasms Neoadjuvant Therapy Immunotherapy Molecular Targeted Therapy

Start date: 2025-06-15
Primary completion: 2027-12-31
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.